PATH vs SRPT
Uipath Inc (PATH) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the PATH and SRPT stock pages for the full models.
Not investment advice.